CTS's Q4 Earnings Call: Our Top 5 Analyst Questions

CTS Corporation’s fourth quarter was marked by a positive market response, driven by strong execution of its diversification strategy and momentum in non-transportation end markets. Management highlighted that diversified segments, particularly medical and industrial, delivered robust revenue gains, offsetting flat transportation sales. CEO Kieran O’Sullivan attributed performance to the company’s focus on advanced sensing technologies and operational improvements, stating, “Our diversified end markets were up 16% versus the prior year period.” Medical applications, especially in therapeutic and diagnostic devices, stood out as key contributors, while ongoing gross margin expansion reflected both product mix and process enhancements.

Is now the time to buy CTS? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From CTS’s Q4 Earnings Call

• Hendi Susanto (Gabelli Funds) asked about assumptions for the smart actuator platform and dual sourcing by customers. CEO Kieran O'Sullivan confirmed ongoing launches and cost reduction efforts, indicating confidence in future adoption.
• Hendi Susanto (Gabelli Funds) requested insights into new products for transportation and diversified end markets. O'Sullivan pointed to $100 million in new business awards—including floor hinge and drive pad technologies—and strong momentum in medical therapeutics and diagnostics.
• John Franzreb (Sidoti and Co.) questioned the timing of SideQuest revenue, noting deferrals in government contracts. O'Sullivan clarified that revenue was lighter due to funding cycles but expects normalization and new contracts in the coming year.
• John Franzreb (Sidoti and Co.) inquired about the proportion of revenue from new product introductions versus end-of-life programs. CFO Ashish Agrawal explained that diversified markets see faster revenue recognition from new products, while transportation awards have longer lead times.
• John Franzreb (Sidoti and Co.) asked about visibility in the industrial segment and whether trends were improving. O'Sullivan affirmed a steady improvement, citing higher bookings and a favorable book-to-bill ratio.

Catalysts in Upcoming Quarters

In future quarters, the StockStory team will be watching (1) the continued acceleration of medical and industrial sales as a sign of sustained diversification progress, (2) the pace of recovery in government-related defense revenues, especially as funding cycles normalize, and (3) signs of stabilization or improvement in transportation, particularly from new EV-focused product launches. The impact of tariffs and supply chain dynamics, as well as execution on new customer programs, will also be important factors to monitor.

CTS currently trades at $57.46, up from $55.58 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).

High-Quality Stocks for All Market Conditions

If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.

Don’t wait for the next volatility shock. Check out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.